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Background: There is a strong association between weight gain and metabolic events in patients with schizophrenia
receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index
(BMI) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate (PP) in a
long-term trial.
Methods: We conducted a post hoc analysis of data from a PP study that included a 33-week open-label transition (TR)
and maintenance phase; a variable duration, randomized, double-blind (DB), placebo-controlled phase and a 52-week
open-label extension (OLE) phase. Overall, 644 patients received PP continuously from study entry through
discontinuation or study completion and were grouped by baseline BMI (kg/m2): underweight (BMI <19; n = 29,
4.5%), normal-weight (BMI 19- < 25; n = 229, 35.6%), overweight (BMI 25- < 30; n = 232, 36.0%) and obese (BMI ≥30;
n = 154, 23.9%). Metabolic treatment-emergent adverse events (TEAEs) and changes in related laboratory results from TR
baseline were analyzed.
Results: PP exposure was similar across BMI groups; overall mean (SD) dose/month was 70.3 (17.17) mg eq. [109.6 (26.78)
mg]; median duration of exposure was 204 days (6 to 1009 days). Occurrences of metabolic TEAEs overall by group were
0% (underweight), 14.9% (normal-weight), 14.7% (overweight), and 24.0% (obese). The most common (≥2%) metabolic
TEAE were weight gain and elevated blood levels of glucose, lipids, and insulin. Mean BMI and weight increased in
normal-weight and overweight groups at DB endpoint, and in underweight, normal-weight and overweight groups at
OLE endpoint (p ≤0.05). No consistent trend for increased metabolic-related laboratory values by baseline BMI group was
observed. Homeostatic model assessments for insulin resistance indicated preexisting insulin resistance at baseline, with
minimal changes at OLE endpoint across baseline BMI groups.
Conclusion: Occurrences of metabolic-related TEAEs trended with greater BMI status in patients with schizophrenia
treated with PP; consistent trends in metabolic-related laboratory values were not observed.
Trial registration: This study is registered at ClinicalTrials.gov (NCT 00518323).
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Schizophrenia is a chronic mental illness that requires
long-term antipsychotic treatment to both manage
disease symptoms and delay relapses [1]. Second gen-
eration antipsychotics (SGAs) are generally preferred over
typical antipsychotics for schizophrenia treatment as they
are associated with fewer extrapyramidal symptoms, lower* Correspondence: jkernsli@its.jnj.com
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reproduction in any medium, provided the orrisk of tardive dyskinesia, and possibly greater im-
provement in negative symptoms [2]. However, several
SGAs are known to be associated with a high risk of
metabolic adverse effects such as weight gain, hyperlip-
idemia and hyperglycemia [2,3]. Glucose dysregulation
[4], glucose intolerance [5] and increased cholesterol
levels [6] can occur in patients taking SGAs and there
is a high prevalence of metabolic syndrome, especially
in women (52%) compared with men (36%) with
schizophrenia [7]. Additionally, obese and overweighttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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metabolic adverse effects than those with normal-
weight [8]. These metabolic complications increase the
risk for cardiovascular diseases, insulin resistance and
diabetes mellitus, and can lead to increased morbidity
and mortality, in addition to impairing patient adher-
ence to medication [9]. Several consensus panels have
recommended regular monitoring of metabolic bio-
markers in patients with schizophrenia [10-12].
Paliperidone palmitate (PP), a long-acting injectable
(LAI) administered once-monthly (after an initiation
regimen of two injections: 150 milligram equivalents
(mg eq.) [234 mg] on day 1, followed by 100 mg eq.
[156 mg] one week later), has been shown to be effect-
ive for the treatment of schizophrenia [13]. We con-
ducted a post hoc analysis of data from a long-term
(up to 3 years) multiphase, recurrence prevention
study [14,15] to examine the metabolic effects of ex-
tended PP treatment in patients with schizophrenia




The inclusion and exclusion criteria for patients in-
cluded in this study are reported in detail elsewhere
[14,15]. In brief, men and women, aged 18 to 65 years
(inclusive), having BMI ≥15.0 kg/m2 with a diagnosis
of schizophrenia (Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition [DSM-IV], criteria) for at
least 1 year before screening, and a Positive and Nega-
tive Syndrome Scale (PANSS) total score below 120, at
screening and baseline were included. Patients were ex-
cluded if they had an active DSM-IV diagnosis other
than schizophrenia or significant risk of suicidal or ag-
gressive behavior or a suspected history of substance
dependence according to the DSM-IV criteria in the
3 months before screening.
For this post hoc analysis, patients who received PP
continuously from study entry through discontinuation or
study completion were included. Data were grouped accord-
ing to patients’ baseline BMI: underweight (BMI <19 kg/
m2), normal-weight (BMI 19 - <25 kg/m2), overweight (BMI
25 - <30 kg/m2) and obese (BMI ≥30 kg/m2).
The study protocol was approved by an Independent
Ethics Committee (Comité Ético Científico Universidad
de Ciencias Médicas [UCIMED], Costa Rica; Comité de
Ética del Centro de Investigación y Extensión de Ciencias
de la Salud del Instituto Tecnológico de Estudios
Superiores de Monterrey, Mexico; Comité de Ense-
ñanza, Investigación, Capacitación y Ética, Comité de
Ética e Investigación Clínica, Mexico; Clinical Trials
Department- National Medicines Agency/The National
Ethics Committee for the Clinical Trial Study of Medicines,Romania; Independent Interdisciplinary Committee on Eth-
ical Expertise of Clinical Studies, Russia; Pharma-Ethics,
South Africa; Central Ethics Commission of the Ministry of
Public Health of Ukraine Kornatskyy, Ukraine) or Institu-
tional Review Board (Korea, Taiwan, Sterling Institutional
Review Board, USA) at each study site; ethical standards
were followed in accordance with the Declaration of
Helsinki and consistent with ICH Good Clinical Practices,
along with local regulatory requirements. All participants
provided written informed consent.Study medication and design
Doses of PP can be expressed both in terms of milli-
grams of PP and milligram equivalents of the pharmaco-
logically active fraction, paliperidone; 39, 78, 117, 156,
and 234 mg doses of PP equate to 25, 50, 75, 100, and
150 mg eq. of paliperidone, respectively.
The study consisted of a 9-week open-label transition
(TR) phase, a 24-week open-label maintenance phase,
a randomized double-blind (DB), placebo-controlled,
relapse prevention phase of variable duration, and an
optional 52-weeks open-label extension (OLE) phase. In
the open-label TR phase, the eligible patients were
switched from their previous antipsychotic to an initial
regimen of 50 mg eq. PP on days 1 and 8 in the gluteal
muscle, followed by a flexibly-dosed PP (25, 50, or
100 mg eq.) once-monthly, in the gluteal muscle. Pa-
tients with stable PANSS score (defined as ≤75 at week
9) entered the maintenance phase and received flexibly-
dosed PP for the first 12 weeks, with dose adjustments
based on patient’s clinical need, followed by 12 weeks of
treatment at the established dose. Patients who were
stable on fixed dose PP during the maintenance phase
were randomized in a 1:1 ratio to continue to receive PP
once-monthly or placebo. In the OLE phase, patients re-
ceived initial dose of 50 mg eq. followed by flexible-dose
of 25, 50, 75, or 100 mg eq. PP once-monthly. Doses
were titrated up or down in increments of 25 mg eq. at
the investigator’s discretion once-monthly for 12 dosing
intervals.Data analysis
Only patients who received PP continuously from
study entry through discontinuation or study comple-
tion in the DB and OLE phases were included in data
analyses using intent-to-treat (ITT) analysis set, which
included patients who received at least 1 dose of PP
during the study.
Metabolic treatment-emergent adverse events (TEAEs)
were identified using Medical Dictionary for Regulatory
Activities (MedRA) preferred terms. All adverse events
that occured between the trial reference start and end
date were included. Changes in weight, BMI, glucose,
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OLE endpoint were analyzed using a paired t-test; no
multiplicity adjustment was incorporated. No between-
group comparisons were conducted. The effect of PP on
glucose homeostasis was assessed by homeostatic model
assessments (HOMA), which measured insulin resist-
ance (HOMA-IR) and β-cell function (HOMA-%β) [16].
The HOMA-IR and HOMA-%β values were summa-
rized descriptively. Unadjusted geometrics means and
ranges were provided for HOMA-IR and HOMA-%β.
This method was applied across all ethnic groups.
Results
Patient disposition, baseline characteristics and
demographics
A total of 644 patients met the criteria for inclusion in
this analysis, of which 183 completed the study through
OLE endpoint. Patient’s choice was the most common
(23%) reason for discontinuation, followed by discontinu-
ation due to adverse event (8%) (Figure 1). Only one patient
in the overweight group discontinued due to a metabolic-
related adverse event (weight gain) during the DB phase.
Majority of patients were men (59%) and white (60%).
The baseline demographic and clinical characteristics
were similar across the groups, except race (Table 1).
There was a higher proportion of blacks in the obese
group compared with other races. The overall mean (SD)
dose of PP during the study was 70.3 (17.17) mg eq. perFigure 1 Patient disposition. DB- double-blind; OLE- open-label extensiomonth. The median duration of PP exposure during the
study was 204 days (6 to 1009 days). The mean doses and
median duration of PP exposure were similar among all
the BMI-based groups.
Treatment-emergent adverse events
At least one TEAE from TR baseline to OLE endpoint was
reported in more than 70% of patients in each of the BMI
groups, except in the underweight group (55%). The most
frequently occurring TEAEs (≥5% overall) were insomnia
(18%), anxiety (13%), worsening of schizophrenia (11%) and
psychotic disorders (6%). Other TEAEs reported in ≥5% of
patients in any of the BMI groups were agitation, hallucin-
ation, paranoia, headache, dizziness, akathisia, increased
weight, nasopharyngitis and nausea (Figure 2, Additional
file 1). Two patients in the normal-weight group and one
patient in the obese group died during the open-label phase
of the study (committed suicide [n = 1], accident [n = 1]
and stroke [n = 1]). No clear association of higher baseline
BMI with increasing incidence of commonly occurring
TEAEs was observed in the study.
However, the occurrence of metabolic-related TEAEs
appeared to differ by BMI status. The obese group expe-
rienced the highest overall rate (n = 37/154, 24%) of any
metabolic TEAEs and highest rate of most of the specific
metabolic-related TEAEs (Figure 3). The overall inci-
dence of metabolic-related TEAEs for the normal-weight
(N = 34/229, 14.9%) and the overweight group (N = 34/n; TR-MA- transition and maintenance.





19- < 25 kg/m2
(n = 229)
Overweight







Age (yrs), Mean (SD) 33.2 (11.20) 36.2 (10.57) 38.2 (10.85) 38.4 (9.81) 37.3 (10.58)
Men, n (%) 19 (65) 146 (64) 143 (62) 71 (46) 379 (59)
Race, n (%)
White 19 (66) 147 (64) 139 (60) 82 (53) 387 (60)
Black 3 (10) 30 (13) 37 (16) 50 (32) 120 (19)
Asian 6 (21) 46 (20) 47 (20) 18 (12) 117 (18)
Other 1 (3) 6 (3) 9 (4) 4 (3) 20 (3)
Baseline BMI (kg/m2), Mean (SD) 18.0 (0.87) 22.5 (1.52) 27.1 (1.34) 35.4 (4.68) 27.0 (5.88)
Age at diagnosis of schizophrenia (years), Mean (SD) 25.4 (8.57) 25.4 (7.39) 26.0 (8.99) 25.4 (8.95) 25.6 (8.41)
Baseline total PANSS, Mean (SD) 77.1 (17.20) 71.4 (17.09) 72.6 (18.82) 72.8 (16.91) 72.4 (17.70)
Prior hospitalization, n (%)
None 3 (10) 26 (11) 18 (8) 16 (10) 63 (10)
Once 6 (21) 55 (24) 47 (20) 29 (19) 137 (21)
Twice 9 (31) 49 (21) 48 (21) 40 (26) 146 (23)
Three times 4 (14) 32 (14) 46 (20) 23 (15) 105 (16)
Four times or more 7 (24) 67 (29) 73 (31) 46 (30) 193 (30)
BMI-body metabolic index; PANSS-Positive and Negative Symptom Scale score; SD-standard deviation.
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were reported in the underweight group (N = 29). The
most commonly (>2%) occurring metabolic TEAEs by
BMI group were weight gain (normal-weight: 11.4%, over-
weight: 7.3%, obese: 11.7%), elevated blood glucose levels
(normal-weight: 2.2%, overweight: 3.9%, obese: 4.6%), andFigure 2 Treatment-emergent adverse events in ≥5% of patients in
○ Underweight <19 kg/m2 (n = 29) Δ Normal-weight 19- < 25 kg/m2 (n =
(n = 154) ● Overall (n = 644). BMI- body mass index; TR- transition; OLE-increased levels of cholesterol (normal-weight: 2.6%, over-
weight: 1.3%, obese: 4.6%), triglyceride (normal-weight:
2.6%, overweight: 1.3%, obese: 3.9%), low density lipopro-
tein (LDL) (normal-weight: 1.8%, overweight: 0.4%, obese:
2.6%) and insulin (normal-weight: 0.9%, overweight: 1.7%,
obese: 4.6%) (Figure 3, Additional file 1).Percent
any BMI-based group from TR baseline to OLE endpoint.
229) □ Overweight 25- < 30 ◊ kg/m2 (n = 232) Obese ≥30 kg/m2
open-label extension.
Percent (%)
Figure 3 Metabolic-related adverse events from TR baseline to OLE endpoint. ○ Underweight <19 kg/m2 (n = 29) Δ Normal-weight 19- < 25 kg/m2
(n = 229) □ Overweight 25-◊ <30 kg/m2 (n = 232) Obese ≥30 kg/m2 (n = 154) ● Overall (n = 644). OLE- open-label extension; TR-transition.
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From TR baseline to DB endpoint (a median duration of
156 days), the mean [SD] weight gain in normal-weight and
overweight groups were significant (2.40 [4.99] kg; p <0.001
and 1.68 [5.17] kg; p = 0.008, respectively) (Figure 4).
During this phase, a weight increase of ≥7% was ob-
served in 5% of patients in the normal-weight and obese
groups and in 8% of patients in the overweight group.
From TR baseline to OLE endpoint (a median durationFigure 4 Mean (SD) weight at TR baseline, DB endpoint and OLE end
TR baseline scores and calculated using paired t-test. Baseline values are fo
data were available. DB- double-blind; OLE- open-label extension; TR transiof 204 days, range = 6 to 1009 days), all BMI-based
groups, except the obese group (mean[SD], 0.79 [11.12]
kg; p = 0.645), showed significant increases in mean
weight (mean[SD], 3.48 [5.99] kg; p < 0.001 for normal-
weight group; 1.62 [4.84] kg; p = 0.003 for overweight
group); the increase was greatest in the underweight
group (mean[SD], 3.82 [4.83] kg; p = 0.0450) (Figure 4).
A weight increase of ≥7% from TR baseline to OLE end-
point was observed in 15% of patients in the normal-point (ITT analysis set). *p ≤ 0.05; p values are based on change from
r those patients for whom both TR baseline and DB (or OLE) endpoint
tion; SD- standard deviation.
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and 6% of patients in the obese group.
A shift towards a higher BMI category was observed
in some patients from TR baseline to DB endpoint (60%
[3/5] of patients in underweight group, 18% [13/71] of
patients in normal- weight group, and 9% [6/70] of pa-
tients in overweight group) as well as from TR baseline
to OLE endpoint (67% [6/9] of patients in underweight
group, 28% [25/89] of patients in normal-weight group,
and 16% [11/70] of patients in overweight group) (Figure 5).
However, a few patients from the overweight and obese
groups moved to a lower BMI category (TR baseline to DB
endpoint: 7% [5/70] moved from overweight to normal-
weight group and 9% [5/54] moved from overweight to
obese group; TR baseline to OLE endpoint: 9% [8/84]
moved from overweight to normal-weight group and 19%
[8/43] moved from obese to overweight group).
Changes in glucose and lipid levels
Mean glucose levels increased significantly from TR
baseline to both DB and OLE endpoints in the over-
weight group, and from TR baseline to OLE endpoint
in the normal-weight group (Table 2). An abnormally
high (>300 mg/dL; single observation meeting criteria)
blood glucose level was observed in one patient each
from the overweight and obese groups from TR base-
line to DB endpoint. From TR baseline to OLE end-
point, 2 out of 85 patients in the normal-weight group
and one out of 41 patients from obese group had ab-
normally high blood glucose levels (single observation
meeting criteria).Figure 5 Mean (SD) BMI at TR baseline, DB endpoint and OLE endpoi
baseline scores and calculated using paired t-test. Baseline values are for th
data were available. DB- double-blind; OLE- open-label extension; TR- transThe decrease in mean (SD) cholesterol (mg/dL) levels
from TR baseline to DB endpoint was −10.20 (36.27) for
underweight, -1.65 (28.87) for normal-weight, -8.91 (26.99)
for overweight, and −17.25 (34.78) for obese groups. How-
ever, cholesterol levels increased in the normal-weight and
obese groups from TR baseline to OLE endpoint (Table 2).
None of the patients showed abnormal (>300 mg/dL) eleva-
tion in cholesterol from TR baseline to DB endpoint and
only one out of 84 patients in the normal-weight group had
an abnormally high cholesterol level from TR baseline to
OLE endpoint.
Mean LDL levels decreased in all the BMI groups, ex-
cept the normal-weight group, from TR baseline to DB
endpoint, and the reduction was numerically greater in
the overweight and obese groups than in the normal and
underweight groups. From TR baseline to OLE end-
point, LDL levels increased significantly (p = 0.024) in
patients from the normal-weight group (Table 2). Ab-
normal increases (>160 mg/dL) in LDL levels from TR
baseline to DB endpoint occurred in 4% (2/45) of pa-
tients in the normal-weight group and 3% (1/38) of
patients in the obese group. In addition, abnormal in-
creases in LDL levels from TR baseline to OLE endpoint
occurred in 5% (3/56) of patients in the normal-weight
group, 6% (3/53) of patients in the overweight group and
10% (3/30) of patients in the obese group.
There was no significant difference in mean insulin,
high density lipoprotein (HDL) or triglyceride levels
from baseline to DB and OLE endpoints throughout the
study (Table 2). An abnormal increase (>500 mg/dL) in
triglyceride levels was observed in 2% (1/51) of patientsnt (ITT analysis set). *p ≤ 0.05; p values are based on change from TR
ose patients for whom both TR baseline and DB (or OLE) endpoint
ition; SD- standard deviation.
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ITT analysis set with DB endpoint
n 5 70 68 52
TR baseline 89.8 (14.65) 92.6 (15.26) 93.8 (12.88) 101.3 (20.02)
Change from TR baseline to DB endpoint 14.6 (18.39) 2.0 (17.89) 7.0 (20.81) −2.1 (24.20)
p-value 0.1506 0.3563 0.0068 0.5313
ITT analysis set with OLE endpoint
n 8 85 77 39
TR baseline 90.4 (11.22) 92.88 (19.71) 94.64 (12.01) 100.33. (15.59)
Change from TR baseline to OLE endpoint 3.9 (18.36) 10.2 (29.17) 9.9 (29.00) 3.5 (30.34)
p-value 0.5694 0.0019 0.0036 0.4772
Insulin, (μU/mL)
ITT analysis set with DB endpoint
n 4 61 63 50
TR baseline 17.0 (13.44) 11.5 (15.23) 12.6 (11.43) 25.6 (32.12)
Change from TR baseline to DB endpoint −2.5 (4.36) −0.6 (16.56) 3.2 (21.64) −4.3 (21.25)
p-value 0.3345 0.7900 0.2517 0.1562
ITT analysis set with OLE endpoint
n 7 72 76 40
TR baseline 12.3 (11.23) 11.1 (14.16) 14.0 (12.37) 25.0 (34.45)
Change from TR baseline to OLE endpoint 0.3 (17.59) 0.8 (13.71) 1.5 (19.62) −5.25 (36.13)
p-value 0.9671 0.6288 0.4928 0.3642
Cholesterol, (mg/dL)
ITT analysis set with DB endpoint
n 5 71 64 52
TR baseline 170.8 (27.09) 180.1 (39.40) 192.7 (34.14) 203.3 (39.23)
Change from TR baseline to DB endpoint −10.2 (36.27) −1.7 (28.87) −8.9 (26.99) −17.2 (34.78)
p-value 0.5636 0.6320 0.0104 0.0008
ITT analysis set with OLE endpoint
n 8 85 75 40
TR baseline 161.9 (26.55) 176.6 (34.37) 194.0 (33.87) 199.3 (31.05)
Change from TR baseline to OLE endpoint −3.25 (28.96) 7.9 (30.87) −1.0 (36.04) 1.0 (22.43)
p-value 0.7602 0.0202 0.8034 0.7741
HDL, (mg/dL)
ITT analysis set with DB endpoint
n 5 71 64 51
TR baseline 60.0 (6.44) 55.9 (16.53) 51.0 (12.16) 46.5 (14.16)
Change from TR baseline to DB endpoint −2.8 (2.86) −1.6 (12.83) 0.13 (8.93) −0.2 (9.27)
p-value 0.0941 0.2828 0.9112 0.8805
ITT analysis set with OLE endpoint
n 8 85 75 39
TR baseline 56.7 (8.38) 53.6 (14.15) 50.7 (12.31) 48.1 (10.75)
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Table 2 Metabolic parameters at TR baseline, DB endpoint and OLE endpoint (ITT analysis set) (Continued)
Change from TR baseline to OLE endpoint −0.2 (7.92) 0.3 (13.46) −1.6 (10.75) 1.0 (10.92)
p-value 0.9314 0.8095 0.1869 0.5514
LDL, (mg/dL)
ITT analysis set with DB endpoint
n 5 71 61 45
TR baseline 85.4 (18.80) 101.7 (34.37) 113.2 (30.01) 126.3 (35.45)
Change from TR baseline to DB endpoint −6.0 (23.64) 0.2 (26.18) −9.6 (23.10) −18.8 (28.82)
p-value 0.6007 0.9388 0.0020 0.0001
ITT analysis set with OLE endpoint
n 8 82 72 38
TR baseline 83.2 (20.35) 99.9 (30.97) 113.3 (28.35) 122.9 (28.98)
Change from TR baseline to OLE endpoint 1.7 (21.67) 6.8 (26.86) −0.1 (30.29) −2.1 (20.97)
p-value 0.8259 0.0249 0.9814 0.5347
Triglycerides, (mg/dL)
ITT analysis set with DB endpoint
n 5 71 64 52
TR baseline 124.4 (95.27) 111.4 (57.31) 155.6 (132.87) 172.2 (101.48)
Change from TR baseline to DB endpoint −5.4 (79.94) −1.8 (54.93) −8.5 (129.2) −0.8 (97.12)
p-value 0.8872 0.7813 0.5985 0.9535
ITT analysis set with OLE endpoint
n 8 85 75 40
TR baseline 107.7 (77.00) 117.00 (72.70) 158.7 (134.11) 150.5 (67.13)
Change from TR baseline to OLE endpoint −22.6 (65.95) 5.3 (87.44) −3.57 (135.8) 13.8 (65.18)
p-value 0.3642 0.5765 0.8203 0.1875
TR- transition; DB- double-blind; OLE- open-label extension; ITT- Intent-to-treat.
Changes from TR baseline to DB endpoint or OLE endpoint were calculated using data from those patients belonging to ITT analysis set with DB or OLE endpoint.
All data values are expressed as mean (SD) and p-values are based on change from TR baseline scores and calculated using paired t-test.
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and in 1% (1/85) of patients in the normal-weight group
from TR baseline to OLE endpoint. None of the patients
showed an abnormal decrease (<35 mg/dL) in HDL
levels throughout the study.
Homeostatic model assessments
HOMA-IR geometric mean values were >1 in all BMI
groups at baseline, indicating preexisting insulin resist-
ance [17]. There was minimal change in the HOMA-IR
geometric mean values from TR baseline to OLE end-
point across all baseline BMI groups (Table 3). Baseline
geometric mean HOMA-%β values were above normal
(defined as >100) in overweight and obese groups, indi-
cating higher β-cell function [17]. At OLE endpoint,
HOMA-%β values decreased from TR baseline in the
normal-weight, overweight and obese groups. In the
underweight group, the HOMA-%β values increased
from below to above normal from TR baseline to OLE
end point (Table 3).Discussion
Metabolic adverse effects, especially abnormal lipid and
glucose metabolism, are a particular concern in patients
with schizophrenia receiving SGAs [18-21]. Baseline
BMI has been shown to be a potential predictor of in-
creased risk of such metabolic events [8]. Therefore, we
conducted a post hoc analysis of data from a long-term
multiphase, recurrence prevention trial of PP in patients
with schizophrenia [14,15] to assess the occurrence of
metabolic events by baseline BMI.
We found no clear pattern, by BMI group, in general
TEAEs, but the obese group had the highest occurrence of
metabolic-related TEAEs, indicating that higher BMI is
potentially associated with higher risk of metabolic-related
adverse events. Patients in the underweight group had the
lowest incidence of overall TEAEs compared with other
baseline BMI groups, and experienced no metabolic-
related TEAEs. Adverse changes in metabolic-related la-
boratory values did not appear to consistently correlate
with BMI, however. Reported TEAEs (both overall and
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N 22 191 200 133 546
Geometric Mean 1.5 1.7 2.4 4.3 2.4
Range (0.66, 3.56) (0.74, 3.99) (1.11, 5.14) (1.86, 9.85) (0.99, 5.85)
DB endpoint
N 4 62 60 52 178
Geometric Mean 2.5 2.0 2.6 3.8 2.6
Range (0.75, 8.17) (0.84, 4.64) (1.13, 5.80) (1.64, 8.86) (1.09, 6.33)
OLE endpoint
N 8 76 71 40 195
Geometric Mean 1.9 2.0 2.6 4.2 2.6
Range (0.73, 4.81) (0.78, 5.03) (0.99, 6.97) (2.19, 8.25) (1.00, 6.56)
HOMA-%β
TR baseline
N 22 191 200 133 546
Geometric Mean 90.4 93.8 123.4 175.9 120.7
Range (50.65, 161.25) (46.18, 190.64) (63.20, 240.9) (82.53, 374.68) (57.47, 53.47)
DB endpoint
N 4 62 60 52 178
Geometric Mean 84.7 100.2 105.9 167.1 118.1
Range (21.50, 333.65) (46.54, 215.73) (59.91, 187.1) (88.5, 315.3) (57.8, 241.2)
OLE endpoint
N 8 76 71 40 195
Geometric Mean 117.0 91.0 100.8 167.9 108.2
Range (50.71, 270.77) (35.65, 232.06) (47.68, 213.29) (91.04, 309.64) (46.99, 49.21)
TR- transition; DB- double-blind; OLE- open-label extension.
HOMA-IR = Homeostatic Model Assessment for Insulin Resistance; HOMA-%β = Homeostatic Model Assessment for β-cell function. *HOMA-IR and HOMA-%β are
expressed as the Geometric Mean (exp [mean {logs} – 1 * SD {logs}], exp [mean {logs} + 1 * SD {logs}]).
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findings of previous studies of PP [22-25].
Weight gain, a common problem of antipsychotic
medication, may lead to noncompliance and certain co-
morbidities such as dyslipidemia, hypertension, diabetes
mellitus, cardiovascular disease, cancers, and osteoarthritis
[9,26]. A previous meta-analysis demonstrated a mean in-
crease in weight in patients receiving standard doses of an-
tipsychotics over a 10-week period: 4.45 kg with clozapine,
4.15 kg with olanzapine, 2.92 kg with sertindole, 2.10 kg
with risperidone, and 0.04 kg with ziprasidone [27]. A
double-blind randomized clinical trial comparing three
SGAs in patients early in the course of psychotic illness
found that at week 12, the olanzapine group had more
weight gain, a greater increase in BMI, and a higher propor-
tion of patients with a BMI increase of at least 1 unit
compared with the quetiapine and risperidone groups.Furthermore, 80% of patients in the olanzapine group had
gained ≥7% of their baseline weight at week 52, compared
with 50% in the quetiapine and 58% in the risperidone
groups [21]. In the present post hoc analysis, moderate
weight gain (0.8-3.8 kg) was observed during the much
longer study period (median = 204 days, range = 6 to
1009 days). More patients in the normal-weight group
had >7% weight gain compared with all other groups.
Even though none of the patients in the underweight
group had >7% weight gain, 60% of these patients
gained weight and thus achieved normal-weight. More
than 50% of patients were followed up to 6 months and
40% of patients were followed up to a year. Although
we were unable to follow these patients long enough to
determine how the course of their weight gain may
continue to change over time, it is possible these pa-
tients’ weight trajectory may follow that of other
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ring during the course of treatment. The weight gain
observed in this analysis is comparable to that ob-
served in previous short-term PP studies, where mod-
erate weight gain (0.9-1.5 kg) was observed over a 13-
week period [18-20]. Similar findings were also seen in
long-term studies with oral paliperidone extended–re-
lease, which showed a mean (SD) increase in body
weight of 1.2 (5.16) kg from OLE baseline to OLE
endpoint [28]. Long-term double-blind, placebo-
controlled schizophrenia relapse prevention studies
with PP and paliperidone extended-release have shown
that increase in body weight is similar between PP and
paliperidone extended-release [29]. The mean weight
gain observed in the present study is thus parallel to
data presented for OLE and short term PP studies. A
prospective study examining the use of PP with weight
reduction or weight maintenance programs would be
valuable.
In addition to their effects on weight gain, SGAs are often
associated with abnormal glucose regulation [2,9,16]. In the
present study, there were no clinically relevant mean
changes in the glucose and serum lipid levels across base-
line BMI groups, similar to findings of earlier short-term
PP studies [22-25]. Previous long-term PP studies also
noted a low proportion of glucose-related TEAEs [24,25].
Further, no clinically relevant lipid changes were observed
in a long-term study with the highest available dose of PP
(150 mg eq.) [30].
The result of this post hoc analysis should be inter-
preted cautiously, as the study was not designed or pow-
ered to demonstrate differences in metabolic-related
TEAEs in subgroups defined by baseline BMI. Addition-
ally, preexisting risk factors in the obese group for meta-
bolic events may contribute to the higher incidence of
metabolic-related TEAEs in this group. The results may
not be broadly applicable to the full spectrum of pa-
tients with schizophrenia due to the specific recruit-
ment criteria for the study, and substantially smaller
sample size for the underweight group. Patients with
schizophrenia are at increased risk for metabolic abnormal-
ities and schizophrenia treatment seems to exacerbate this
risk; these effects could not be assessed in the current study
due to lack of a control arm.Conclusion
This study, with a median duration of PP exposure of
204 days, suggests that occurrences of metabolic-related
TEAEs trend with greater BMI status in patients with
schizophrenia treated with PP. Consistent trends in
metabolic-related laboratory values with BMI status
were not observed. Prespecified studies are needed to
confirm these results.Additional file
Additional file 1: Supplemental information: appendix 1. MedRA
terminology for TEAEs listed in the manuscript.
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